Proactiveinvestors recommends

New Guinea Energy to gain from Talisman, Mitsubishi gas alliance in Papua New Guinea
Elementos succeeding in South American precious and base metal diversification strategy
Greenearth Energy: clean technology program a windfall for energy efficient lighting technology

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	GTG
Latest Price:	0.14 (8.00% )
52-week High:	0.33
52-week Low:	0.07
Market Cap:	62.72M

1 year chart

1 day chart

Genetic Technologies

Genetic Technologies (ASX: GTG, NASDAQ: GENE) is a genetic testing business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA on health.

Genetic Technologies: shares soar 48% prompting ASX please explain

Friday, January 27, 2012 by John Phillips

Genetic Technologies (ASX: GTG) has received a price and volume speeding ticket from the ASX today after the company's shares hit a $0.155 intra-day high, which is 48% higher than the closing price on Wednesday 25 January.

The company said that it not aware of any material information that has not been released to the market, which may explain the sudden investor interest, but did make the following statement in a response back to the ASX:

'... we advise that the company's chief executive officer, Dr. Paul MacLeman recently attended the J.P. Morgan Healthcare Conference in San Francisco during which presentations were made to a number of stock brokers and investment groups.

'No information was contained in these presentations that had not already been released to the market.'

Highlighting how Genetic Technologies continues to move forward, just last month the company entered an agreement with German diagnostic product developer AutoImmun Diagnostika, which has been granted non-exclusive rights to a number of Genetic’s patents covering its non-coding DNA technology.

The agreement provides AutoImmun Diagnostika non-exclusive access to Genetic’s non-coding DNA technology for its products and services.

Genetic Technologies is also in ongoing discussions with companies relating to the use of its non-coding DNA technology.

Cancer diagnostics

Genetic Technologies is using the latest technology to identify changes in DNA to either confirm a diagnosis of a specific disorder of which a person displays signs or symptoms, or to identify individuals at risk of developing a disease before any symptoms appear.

The company is aiming to establish itself as a cancer diagnostics business and the first product launched as part of this strategy is the BREVAGen™ breast cancer risk stratification test.

BREVAGen™, which was launched in the U.S. in June, is a novel genetic test panel that examines a patient's DNA to detect the absence or presence of certain common genetic variations associated with an increased risk for developing breast cancer.

The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient's family and personal history, therefore giving a clearer picture of an individual woman's risk of developing breast cancer.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.